UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial

Annals of oncology, 2017-06, Vol.28 (6), p.1346-1351

2017

Volltextzugriff (PDF)

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

Investigational new drugs, 2014-06, Vol.32 (3), p.555-560

2014

Volltextzugriff (PDF)

2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study

European journal of cancer (1990), 2015-09, Vol.51, p.S528-S528

2015

Volltextzugriff (PDF)

Pharmaceutical research nurse: experience of the national tumour institute of milan

European journal of hospital pharmacy. Science and practice, 2012-04, Vol.19 (2), p.237-238

2012

Volltextzugriff (PDF)

Problems and solutions related to the storage of investigational drugs

European journal of hospital pharmacy. Science and practice, 2012-04, Vol.19 (2), p.208-209

2012

Volltextzugriff (PDF)

Mucositis pain: treatment pptions for the patient

Annals of oncology, 2016-09, Vol.27, p.iv103

2016

Volltextzugriff (PDF)

Dysgeusia in oncological patients: issues and solutions in evaluation

Annals of oncology, 2015-10, Vol.26, p.vi148

2015

Volltextzugriff (PDF)

The role of pharmacists in prevention and management of extravasation

Annals of oncology, 2015-10, Vol.26, p.vi149

2015

Volltextzugriff (PDF)

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

Annals of oncology, 2016-10, Vol.27, p.vi294-vi294

2016

Volltextzugriff (PDF)

APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

Annals of oncology, 2016-10, Vol.27, p.vi293-vi293

2016

Volltextzugriff (PDF)

Dacomitinib as first-line treatment of locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): Interim analysis of an open-label, single-group, phase 2 trial

Annals of oncology, 2016-10, Vol.27, p.vi292-vi292

2016

Volltextzugriff (PDF)

Brentuximab Vedotin in CD30-expressing germ cell tumors after chemotherapy failure

Clinical genitourinary cancer, 2016-08, Vol.14 (4), p.261-264.e4

2016

Volltextzugriff (PDF)

4CPS-188 Galenic preparations and rare diseases: guanidinoacetate methyltransferase deficiency: experience in a local hospital

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A157-A157

2019

Volltextzugriff (PDF)

5PSQ-065 Manic symptomatology induced by alectinib: a case report

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A231-A231

2019

Volltextzugriff (PDF)

APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e373-e374

2017

Volltextzugriff (PDF)

PS-033 Ifosfamide induced encephalopathy: prophylaxis and therapy with methylene blue

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A241-A243

2017

Volltextzugriff (PDF)

CP-004 Analysis of treatment with pembrolizumab in patients with metastatic melanoma in the expanded access programme (EAP)

European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A2-A2

2016

Volltextzugriff (PDF)

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e365-e366

2017

Volltextzugriff (PDF)

Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e1910-e1911

2017

Volltextzugriff (PDF)

20 Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01)

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e20-e20

2016

Volltextzugriff (PDF)

Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase 2 study

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e293-e294

2017

Volltextzugriff (PDF)

Dacomitinib (Daco) induction therapy for locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): An open label, single-arm, phase 2 study

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e1244-e1245

2017

Volltextzugriff (PDF)

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor 3 (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

Investigational new drugs, 2014, Vol.32 (3), p.555-560

2014

Volltextzugriff (PDF)

1144 A phase 2 study of the Aurora Kinase-A (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pre-treated urothelial cancer (UC)

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e1144-e1144

2016

Volltextzugriff (PDF)

239 Pan-HER trosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemonaive patients (pts)

European urology supplements : official journal of the European Association of Urology, 2016-03, Vol.15 (3), p.e239-e239

2016

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study

Pharmaceutical research nurse: experience of the national tumour institute of milan

Problems and solutions related to the storage of investigational drugs

Mucositis pain: treatment pptions for the patient

Dysgeusia in oncological patients: issues and solutions in evaluation

The role of pharmacists in prevention and management of extravasation

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

Dacomitinib as first-line treatment of locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): Interim analysis of an open-label, single-group, phase 2 trial

Brentuximab Vedotin in CD30-expressing germ cell tumors after chemotherapy failure

4CPS-188 Galenic preparations and rare diseases: guanidinoacetate methyltransferase deficiency: experience in a local hospital

5PSQ-065 Manic symptomatology induced by alectinib: a case report

APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

PS-033 Ifosfamide induced encephalopathy: prophylaxis and therapy with methylene blue

CP-004 Analysis of treatment with pembrolizumab in patients with metastatic melanoma in the expanded access programme (EAP)

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial

20 Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01)

Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase 2 study

Dacomitinib (Daco) induction therapy for locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): An open label, single-arm, phase 2 study

PF-03446962, a fully-human monoclonal antibody against transforming growth-factor 3 (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

1144 A phase 2 study of the Aurora Kinase-A (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pre-treated urothelial cancer (UC)

239 Pan-HER trosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemonaive patients (pts)

Suchergebnisse filtern